June Ye

3.0k total citations
17 papers, 975 citations indexed

About

June Ye is a scholar working on Endocrinology, Diabetes and Metabolism, Rheumatology and Molecular Biology. According to data from OpenAlex, June Ye has authored 17 papers receiving a total of 975 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Rheumatology and 4 papers in Molecular Biology. Recurrent topics in June Ye's work include Diabetes Treatment and Management (7 papers), Systemic Lupus Erythematosus Research (5 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). June Ye is often cited by papers focused on Diabetes Treatment and Management (7 papers), Systemic Lupus Erythematosus Research (5 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). June Ye collaborates with scholars based in United States, United Kingdom and Japan. June Ye's co-authors include Murray Stewart, Richard E. Pratley, Susan Johnson, Michael A. Nauck, Rhona Scott, Anthony Barnett, Julio Rosenstock, Fernando Ovalle, Mark N. Feinglos and Scott C. Brakenridge and has published in prestigious journals such as Diabetes Care, Critical Care Medicine and Diabetologia.

In The Last Decade

June Ye

17 papers receiving 955 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
June Ye United States 12 524 288 223 215 197 17 975
Julia Lepenies Germany 12 172 0.3× 187 0.6× 75 0.3× 101 0.5× 124 0.6× 16 754
Manou R. Batstra Netherlands 14 113 0.2× 131 0.5× 132 0.6× 59 0.3× 212 1.1× 29 639
Montserrat Miret Switzerland 11 184 0.4× 119 0.4× 97 0.4× 261 1.2× 42 0.2× 13 825
Franco Carmassi Italy 12 144 0.3× 76 0.3× 145 0.7× 101 0.5× 123 0.6× 34 739
Willem R.P. Agema Netherlands 14 62 0.1× 145 0.5× 195 0.9× 205 1.0× 257 1.3× 19 991
Bor‐Shen Hsieh Taiwan 17 226 0.4× 189 0.7× 45 0.2× 66 0.3× 308 1.6× 40 810
Stine E. Nielsen Denmark 12 204 0.4× 150 0.5× 92 0.4× 16 0.1× 95 0.5× 16 903
Talia Diker‐Cohen Israel 16 322 0.6× 208 0.7× 58 0.3× 30 0.1× 163 0.8× 41 757
Ke Jiang China 14 243 0.5× 118 0.4× 49 0.2× 46 0.2× 182 0.9× 32 608
Han-Seob Kim United States 12 131 0.3× 196 0.7× 136 0.6× 80 0.4× 122 0.6× 15 691

Countries citing papers authored by June Ye

Since Specialization
Citations

This map shows the geographic impact of June Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by June Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites June Ye more than expected).

Fields of papers citing papers by June Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by June Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by June Ye. The network helps show where June Ye may publish in the future.

Co-authorship network of co-authors of June Ye

This figure shows the co-authorship network connecting the top 25 collaborators of June Ye. A scholar is included among the top collaborators of June Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with June Ye. June Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Thaçi, Diamant, Bruce Strober, Kenneth B. Gordon, et al.. (2022). Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 12(2). 495–510. 38 indexed citations
2.
Fleischmann, Roy, Michael E. Weinblatt, Michael A. Maldonado, et al.. (2019). Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatology and Therapy. 6(4). 559–571. 11 indexed citations
3.
Hotchkiss, Richard S., Elizabeth Colston, Sachin Yende, et al.. (2019). Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Medicine. 45(10). 1360–1371. 136 indexed citations
4.
5.
Hotchkiss, Richard S., Elizabeth Colston, Sachin Yende, et al.. (2019). Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*. Critical Care Medicine. 47(5). 632–642. 167 indexed citations
6.
Baker, Joshua F., Mikkel Østergaard, Paul Emery, et al.. (2019). Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. Arthritis Care & Research. 72(7). 959–964. 4 indexed citations
7.
8.
D’Agostino, Maria Antonietta, Rieke Alten, Eduardo Mysler, et al.. (2017). Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. Clinical Rheumatology. 36(12). 2655–2665. 25 indexed citations
9.
Bandyopadhyay, Somnath, Seán Connolly, Omar Jabado, et al.. (2017). Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. Lupus Science & Medicine. 4(1). e000206–e000206. 10 indexed citations
10.
Colston, Elizabeth, Sachin Yende, Derek C. Angus, et al.. (2017). 1504: IMMUNE CHECKPOINT INHIBITORS IN SEPSIS: A PHASE 1B TRIAL OF ANTI-PD-L1 (BMS-936559). Critical Care Medicine. 46(1). 736–736. 4 indexed citations
11.
Yang, Fred, David L. DeMets, Murray Stewart, & June Ye. (2015). Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes Metabolic Syndrome and Obesity. 8. 315–315. 8 indexed citations
12.
O'Connor‐Semmes, Robin, Susan Walker, Anita Kapur, et al.. (2015). Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment. Drug Metabolism and Disposition. 43(7). 1077–1083. 13 indexed citations
13.
Fisher, Miles, Mark C. Petrie, Phil Ambery, et al.. (2015). Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. The Lancet Diabetes & Endocrinology. 3(9). 697–703. 66 indexed citations
14.
Pratley, Richard E., Michael A. Nauck, Anthony Barnett, et al.. (2014). Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. The Lancet Diabetes & Endocrinology. 2(4). 289–297. 264 indexed citations
15.
Seino, Yutaka, Nobuya Inagaki, Mark Bush, et al.. (2014). A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Current Medical Research and Opinion. 30(6). 1095–1106. 27 indexed citations
16.
17.
Mudaliar, Sunder, Debra Armstrong, Robin O'Connor‐Semmes, et al.. (2012). Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes. Diabetes Care. 35(11). 2198–2200. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julia Lepenies Breakdown of academic impact, for papers by Manou R. Batstra Breakdown of academic impact, for papers by Montserrat Miret Breakdown of academic impact, for papers by Franco Carmassi Breakdown of academic impact, for papers by Willem R.P. Agema Breakdown of academic impact, for papers by Bor‐Shen Hsieh Breakdown of academic impact, for papers by Stine E. Nielsen Breakdown of academic impact, for papers by Talia Diker‐Cohen Breakdown of academic impact, for papers by Ke Jiang Breakdown of academic impact, for papers by Han-Seob Kim
Rankless by CCL
2026